Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain activ... Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. Show more
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1161 | -29.8380878951 | 0.3891 | 0.39 | 0.26 | 1113409 | 0.3540958 | CS |
4 | -0.207 | -43.125 | 0.48 | 0.6196 | 0.26 | 607140 | 0.40709572 | CS |
12 | -0.357 | -56.6666666667 | 0.63 | 0.9374 | 0.26 | 424175 | 0.50344128 | CS |
26 | -0.375 | -57.8703703704 | 0.648 | 1.1099 | 0.26 | 344722 | 0.65636371 | CS |
52 | -0.597 | -68.6206896552 | 0.87 | 1.87 | 0.26 | 177170 | 0.67942971 | CS |
156 | -4.207 | -93.90625 | 4.48 | 4.8888 | 0.26 | 75296 | 1.12675344 | CS |
260 | -14.687 | -98.1751336898 | 14.96 | 19.56 | 0.26 | 347401 | 10.05775212 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.